ГОРМОНАЛЬНАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ АГОНИСТОВ И АНТАГОНИСТОВ ЛЮТЕИНИЗИ- РУЮЩЕГО ГОРМОНА РЕЛИЗИНГ ГОРМОНА У БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
К. М. Нюшко, А. А. Крашенинников, М. П. Головащенко et al. · Research and Practical Medicine Journal · 2015
Prostate cancer (PC) is one of the most actual problems of modern oncourology. Hormone therapy (HT) using medical castration is the main method of treatment of patients with metastatic PC. HT with usage of the new class of drugs that block the receptors for luteinizing hormone releasing hormone (LHRH) is a promising and effective method of castration therapy that has a number of significant advantages over the use of analogues LHRH. This article presents a review of studies that compared the effectiveness and side effects of HT using antagonists and analogues LHRH.
Cited by 0 works. doi:10.17709/2409-2231-2014-1-69-73
Authors
References
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer
- Is the flare phenomenon clinically significant?
- The role of diethylstilbestrol in the treatment of prostate cancer
- Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists
- Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists
- Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer
- Gonadotropin-Releasing Hormone Blockers and Cardiovascular Disease Risk: Analysis of Prospective Clinical Trials of Degarelix
- Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix
- An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer